GERMANY PROPOSES SIX Rx-TO-OTC SWITCHES EFFECTIVE JAN. 1, 1995
This article was originally published in The Tan Sheet
Executive Summary
GERMANY PROPOSES SIX Rx-TO-OTC SWITCHES EFFECTIVE JAN. 1, 1995, including two topical nonsteroidal anti-inflammatory drugs indicated for local antirheumatic therapy -- felbinac and flufenamic. Lederle, which is developing topical felbinac as a prescription drug in the U.S., will market the nonprescription product in Germany. Luitpold, a subsidiary of Japan-based Sankyo, will market a flufenamic product. The proposal for nonprescription status of these two products follows the July 1 effective switch date of two other topical NSAIDs -- etofenamate and piroxicam.